中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(7): 1370-1374

Effect of ursodeoxycholic acid on symptoms after severe acute respiratory syndrome coronavirus 2 infection in patients with primary biliary cholangitis and their family members

DOI: 10.12449/JCH240714

  • Department of Gastroenterology，The First Affiliated Hospital of Air Force Medical University，Xi’an 710032，China

Research funding:

Key Research and Development Program of Shaanxi Province (2021ZDLSF02-07)

More Information
  • Corresponding author: HAN Ying， hanying1@fmmu.edu.cn （ORCID： 0000-0003-3046-9507）
  • Received Date: 2023-10-05
  • Accepted Date: 2023-12-12
  • Published Date: 2024-07-25
    Abstract
  •   Objective  To investigate the effect of ursodeoxycholic acid （UDCA） on the symptoms after severe acute respiratory syndrome coronavirus 2 （SARS-CoV-2） infection in patients with primary biliary cholangitis （PBC） and their family member.  Methods  A questionnaire survey was conducted to collect related information from 171 PBC patients who attended The First Affiliated Hospital of Air Force Medical University before March 22， 2023 and 128 family members， including demographic information， comorbidities， UDCA administration， SARS-CoV-2 infection， vaccination， symptoms， therapeutic medication， and the changes in liver disease-related symptoms. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups.  Results  The median age was 51 years in the PBC patients and 49 years in the family members， with no significant difference between the two groups （P>0.05）. Compared with the family member group， the PBC group had significantly lower body mass index （22.2±2.4 kg/m2 vs 23.3±2.9 kg/m2， P<0.001） and proportion of male individuals （10% vs 55%， P<0.001）. All PBC patients received UDCA at a dose of 13‍ ‍—‍ ‍15 mg/kg， and SARS-CoV-2 infection rate was 100% in both groups. The family members had a significantly higher SARS-CoV-2 vaccination rate than the PBC patients （91% vs 57%， P<0.001）. Compared with the family members， the PBC patients had significantly milder symptoms of sneezing， nasal obstruction， chest pain， and abnormal taste （P<0.05）. Compared with the family members， the PBC patients had significantly lower rates of use of compound cold medicine （11% vs 20%， P<0.05） and Lianhua Qingwen capsules （12% vs 21%， P<0.05）. For the PBC patients after SARS-CoV-2 infection， the liver disease-related symptoms such as fatigue， abdominal distension， dry mouth and dry eyes， pruritus， and yellow skin were aggravated by 37%， 2%， 27%， 10%， and 3%， respectively.  Conclusion  Compared with the immediate family members of PBC patients who do not take UDCA， the PBC patients receiving UDCA do not show a reduction in SARS-CoV-2 infection rate， but UDCA may have a certain effect on alleviating infection-related symptoms in such patients. PBC patients may still experience the aggravation of liver disease-related symptoms after SARS-CoV-2 infection， and the long-term effect on PBC patients after SARS-CoV-2 infection should be taken seriously in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    ACOSTA E. Global estimates of excess deaths from COVID-19[J]. Nature, 2023, 613( 7942): 31- 33. DOI: 10.1038/d41586-022-04138-w.
    [2]
    TIAN DD, SUN YH, XU HH, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94( 6): 2376- 2383. DOI: 10.1002/jmv.27643.
    [3]
    HU B, GUO H, ZHOU P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19( 3): 141- 154. DOI: 10.1038/s41579-020-00459-7.
    [4]
    SANYAOLU A, OKORIE C, MARINKOVIC A, et al. Comorbidity and its impact on patients with COVID-19[J]. SN Compr Clin Med, 2020, 2( 8): 1069- 1076. DOI: 10.1007/s42399-020-00363-4.
    [5]
    BERLIN DA, GULICK RM, MARTINEZ FJ. Severe Covid-19[J]. N Engl J Med, 2020, 383( 25): 2451- 2460. DOI: 10.1056/nejmcp2009575.
    [6]
    BREVINI T, MAES M, WEBB GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2[J]. Nature, 2023, 615( 7950): 134- 142. DOI: 10.1038/s41586-022-05594-0.
    [7]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67( 1): 145- 172. DOI: 10.1016/j.jhep.2017.03.022.
    [8]
    WANG L, HAN Y. Diagnosis and treatment of primary biliary cholangitis: Current status and challenges[J]. J Clin Hepatol, 2021, 37( 10): 2257- 2261. DOI: 10.3969/j.issn.1001-5256.2021.10.001.

    王璐, 韩英. 原发性胆汁性胆管炎的诊治现状与挑战[J]. 临床肝胆病杂志, 2021, 37( 10): 2257- 2261. DOI: 10.3969/j.issn.1001-5256.2021.10.001.
    [9]
    WANNER N, ANDRIEUX G, BADIA-I-MOMPEL P, et al. Molecular consequences of SARS-CoV-2 liver tropism[J]. Nat Metab, 2022, 4( 3): 310- 319. DOI: 10.1038/s42255-022-00552-6.
    [10]
    GAZIANO L, GIAMBARTOLOMEI C, PEREIRA AC, et al. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19[J]. Nat Med, 2021, 27( 4): 668- 676. DOI: 10.1038/s41591-021-01310-z.
    [11]
    IOANNOU GN, LOCKE E, GREEN P, et al. Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection[J]. JAMA Netw Open, 2020, 3( 9): e2022310. DOI: 10.1001/jamanetworkopen.2020.22310.
    [12]
    WILLIAMSON EJ, WALKER AJ, BHASKARAN K, et al. Factors associated with COVID-19-related death using OpenSAFELY[J]. Nature, 2020, 584( 7821): 430- 436. DOI: 10.1038/s41586-020-2521-4.
    [13]
    KHANDKER SS, GODMAN B, JAWAD MI, et al. A systematic review on COVID-19 vaccine strategies, their effectiveness, and issues[J]. Vaccines, 2021, 9( 12): 1387. DOI: 10.3390/vaccines9121387.
    [14]
    TEIJARO JR, FARBER DL. COVID-19 vaccines: Modes of immune activation and future challenges[J]. Nat Rev Immunol, 2021, 21( 4): 195- 197. DOI: 10.1038/s41577-021-00526-x.
    [15]
    MATHEW M, JOHN SB, SEBASTIAN J, et al. COVID-19 vaccine triggered autoimmune hepatitis: Case report[J]. Eur J Hosp Pharm, 2023, 30( 5): e27. DOI: 10.1136/ejhpharm-2022-003485.
    [16]
    SHAHRANI S, SOOI CY, HILMI IN, et al. Autoimmune hepatitis(AIH) following coronavirus(COVID-19) vaccine-No longer exclusive to mRNA vaccine?[J]. Liver Int, 2022, 42( 10): 2344- 2345. DOI: 10.1111/liv.15350.
    [17]
    ALBILLOS A, LARIO M, ÁLVAREZ-MON M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance[J]. J Hepatol, 2014, 61( 6): 1385- 1396. DOI: 10.1016/j.jhep.2014.08.010.
    [18]
    NALBANDIAN A, SEHGAL K, GUPTA A, et al. Post-acute COVID-19 syndrome[J]. Nat Med, 2021, 27( 4): 601- 615. DOI: 10.1038/s41591-021-01283-z.
    [19]
    COOPER S, TOBAR A, KONEN O, et al. Long COVID-19 liver manifestation in children[J]. J Pediatr Gastroenterol Nutr, 2022, 75( 3): 244- 251. DOI: 10.1097/MPG.0000000000003521.
    [20]
    DENNIS A, WAMIL M, ALBERTS J, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study[J]. BMJ Open, 2021, 11( 3): e048391. DOI: 10.1136/bmjopen-2020-048391.
    [21]
    ROTH NC, KIM A, VITKOVSKI T, et al. Post-COVID-19 cholangiopathy: A novel entity[J]. Am J Gastroenterol, 2021, 116( 5): 1077- 1082. DOI: 10.14309/ajg.0000000000001154.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (284) PDF downloads(54) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return